Cue Biopharma, Inc.
CUE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $2 | $3 | $0 | $2 |
| % Growth | -27.3% | 601.7% | -73.3% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $2 | $3 | $0 | $2 |
| % Margin | 96.3% | 100% | 100% | 100% |
| R&D Expenses | $5 | $8 | $9 | $7 |
| G&A Expenses | $0 | $4 | $4 | $4 |
| SG&A Expenses | $5 | $4 | $4 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $10 | $12 | $13 | $11 |
| Operating Income | -$8 | -$9 | -$12 | -$10 |
| % Margin | -351% | -292.3% | -2,921.4% | -611.2% |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | -$7 | -$8 | -$12 | -$9 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$7 | -$8 | -$12 | -$9 |
| % Margin | -346.6% | -287.1% | -2,911.4% | -602.5% |
| EPS | -0.07 | -0.089 | -0.17 | -0.13 |
| % Growth | 21.2% | 47.8% | -30.8% | – |
| EPS Diluted | -0.07 | -0.089 | -0.17 | -0.13 |
| Weighted Avg Shares Out | 101 | 95 | 74 | 74 |
| Weighted Avg Shares Out Dil | 101 | 95 | 74 | 74 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $1 | $1 | $0 |
| EBITDA | -$7 | -$8 | -$11 | -$9 |
| % Margin | -339.4% | -258.7% | -2,671.5% | -586.6% |